10-Q: Actuate Therapeutics Reports Q1 2025 Results, Faces Going Concern Uncertainty

Actuate Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Summary

• Actuate Therapeutics, a clinical-stage biopharmaceutical company, reported its financial results for the first quarter of 2025.
• The company is focused on developing therapies for cancers through the inhibition of glycogen synthase kinase-3 (GSK-3).
• Their lead product candidate is elraglusib, currently in Phase 2 trials for metastatic pancreatic cancer and Phase 1/2 for refractory pediatric malignancies.
• For the three months ended March 31, 2025, Actuate Therapeutics reported a net loss of $6.317 million, compared to a net loss of $8.296 million for the same period in 2024.
• Research and development expenses decreased to $3.220 million from $6.860 million year-over-year, primarily due to lower clinical trial expenses.
• General and administrative expenses increased to $3.145 million from $912,824 year-over-year, driven by higher personnel-related costs and public company expenses.
• As of March 31, 2025, the company had cash and cash equivalents of $3.889 million.
• Management anticipates that current cash resources will not satisfy operational and capital requirements beyond the second quarter of fiscal year 2025.
• The company has entered into a Committed Equity Facility with B. Riley Principal Capital II for up to $50 million, but there is no guarantee that sufficient proceeds will be raised.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company is amending employment agreements with key executives, including Daniel Schmitt and Paul Lytle, to adjust compensation and bonus structures, contingent on securing additional financing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the going concern warning and limited cash runway, despite some improvements in net loss and R&D expenses. The reliance on future financing and the uncertainty of the B. Riley facility contribute to the low score.

Positives

• The net loss decreased from $8.296 million in Q1 2024 to $6.317 million in Q1 2025.
• Research and development expenses decreased, primarily due to lower clinical trial expenses.
• The company has a Committed Equity Facility with B. Riley for up to $50 million.
• Executive compensation adjustments are designed to incentivize securing additional financing.

Negatives

• The company has a working capital deficit of $4.905 million as of March 31, 2025.
• The company's cash and cash equivalents are only projected to cover operational and capital requirements through the second quarter of fiscal year 2025.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• General and administrative expenses increased substantially, driven by personnel costs and expenses related to being a public company.

Risks

• The company's ability to continue as a going concern is uncertain without additional funding.
• The success of the Committed Equity Facility with B. Riley is not guaranteed.
• The company is dependent on the success of elraglusib, which is still in clinical development.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's stock price could be highly volatile.
• The company relies on a single manufacturer in China for its drug substance, which could be affected by geopolitical relationships and tariffs.
• The company may not be able to enforce its intellectual property rights throughout the world.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the foreseeable future as it continues its development of, seeks regulatory approval for, and potentially commercializes elraglusib, and potentially seeks to discover and develop additional product candidates. The company's ability to continue as a going concern is dependent on securing additional funding.

Management Comments

• Management anticipates, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy the Company's operational and capital requirements beyond the second quarter of fiscal year 2025.

Industry Context

Actuate Therapeutics operates in the competitive biopharmaceutical industry, focusing on developing novel therapies for cancer. The company's lead product candidate, elraglusib, targets GSK-3, an enzyme involved in tumor cell survival and growth. The company faces competition from other companies developing cancer therapies, including those targeting similar pathways or indications. The success of Actuate Therapeutics will depend on its ability to successfully develop and commercialize elraglusib, as well as its ability to secure additional funding to support its operations.

Comparison to Industry Standards

• It is difficult to compare Actuate Therapeutics directly to industry standards due to its specific focus on GSK-3 inhibition and its stage of development.
• Comparable companies would be other clinical-stage biopharmaceutical firms developing cancer therapies, such as Kura Oncology or Sierra Oncology before its acquisition by GSK.
• These companies often have high R&D expenses and net losses as they advance their product candidates through clinical trials.
• A key metric for comparison would be the cash runway, which for Actuate is currently limited to the second quarter of 2025, indicating a need for immediate financing.
• Other companies in similar situations often pursue partnerships, licensing agreements, or equity financing to extend their runway.

Related Party Transactions

• The company incurred $168,271 in services provided by Pacific BioPharma Logistics, Inc. (PBL) during the three months ended March 31, 2025.
• Richard Kenley, Vice President of Manufacturing for the Company, is an unpaid advisor for PBL, and his spouse is a shareholder in PBL.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment if the company is unable to secure additional funding.
• Employees face uncertainty regarding job security due to the company's financial situation.
• Patients may be impacted by potential delays or termination of clinical trials if the company is unable to continue operations.
• Suppliers and creditors face the risk of non-payment if the company is unable to meet its financial obligations.

Next Steps

• The company needs to secure additional funding to continue operations beyond the second quarter of fiscal year 2025.
• The company will continue to advance elraglusib through clinical trials.
• The company will seek regulatory approval for elraglusib.
• The company will explore potential collaborations, licenses, and other similar arrangements.

Key Dates

Keywords

elraglusib, Actuate Therapeutics, financing, clinical trials, going concern, GSK-3, cancer, biopharmaceutical, net loss, R&D expenses